Artbio company information, Employees & Contact Information

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure PR Newswire

FDA greenlights phase 1 trial of alpha radioligand therapy in mCRPC Urology Times

ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001 PR Newswire

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival BioPharma Dive

From CAR-T to RLT: Enhancing Precision Oncology with ARTBIO’s Radioligands Inside Precision Medicine

Radiopharma-focused Artbio paints path to clinic with $132M series B Fierce Biotech

ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role PR Newswire

ARTBIO raises $132M to fuel alpha radiotherapy push with Pb212 FirstWord Pharma

Artbio attracts $132M as its alpha radioligand program moves into the clinic Endpoints News

ARTBio raises $132 million for radiopharmaceuticals statnews.com

Artbio takes in $132 million for mid-stage prostate cancer candidate The Pharma Letter

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer Business Wire

Radiopharma biotech Artbio raises $132M for cancer therapies Axios

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors BioWorld MedTech

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors PR Newswire

ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline The Pharma Letter

SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States Business Wire

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies PR Newswire

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential PR Newswire

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities Business Wire

J&J’s Margaret Yu named Artbio CMO The Pharma Letter

ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States PR Newswire

Investors pour $90M onto ARTBIO's palette less than 6 months after launching Fierce Biotech

CDMO Nucleus RadioPharma links up with ARTBIO to help produce prostate cancer candidate for clinical trials Fierce Pharma

Artbio launches for alpha-emitting radiopharmaceuticals to treat cancer Chemical & Engineering News

ARTBIO Raises $132M in Series B Financing FinSMEs